Month: September 2013
A healthy BMI during pregnancy leads to fewer complications: study
The Venus Factor Now Helps Women Boost Metabolism, Lose Fat
Soccer-Player breaks three teeth tackling opponent with his head
BUENOS AIRES, Sept 23 (Reuters) – Argentinos Juniors midfielder Gaspar Iniguez broke three teeth when he prevented Cristian Erbes of Boca Juniors from launching a counter-attack by beating him to the ball with his head. Iniguez dived to head the ball when it was barely a few centimetres off the ground believing he could get there before Erbes two minutes from the end of the 0-0 draw in the Argentine “Inicial” championship on Sunday. “In a gesture of impressive bravery…(Iniguez) dived head first to cut out a counter-attack… …
The Best Carbs for Weight Loss
Americans say they’re creatures of simple, solo exercise habits
By Dorene Internicola NEW YORK (Reuters) – Exercise trends come and go as step aerobics yield to interval training, weight machines are tossed for medicine balls and Pilates falls in and out of fashion. But when it comes to exercise habits, Americans say they prefer to stick to what's simple, solo and short. Nearly 75 percent of 1,200 adults, aged 24 to 44, questioned in an online survey about exercise habits said they worked out at least once a week and 77 percent prefer to do it alone. …
Porn addiction changes the brain: study
Syngenta may be template as Novartis reviews non-core assets
By Caroline Copley ZURICH (Reuters) – Novartis may take a leaf out of its past deal-book as the Swiss drugmaker conducts a review into some of its underperforming businesses, a board member said. New chairman Joerg Reinhardt has launched a review of the drugmaker’s portfolio fanning speculation that some of the company’s smaller units could be sold, spun-off or integrated into other divisions. …
Too much sun may not always be a bad thing: study
What Will the Internet Be in 2050?
Alnylam’s gene therapy shows strong efficacy data
(Reuters) – Alnylam Pharmaceuticals Inc said its experimental gene-based therapy reduced the level of a disease-causing protein, which leads to a rare organ-damaging hereditary disorder, in an early-stage trial. The therapy was also found to be generally safe and well tolerated, Alnylam said in a statement. The trial was testing Alnylam’s subcutaneously delivered therapy for the treatment of an inherited, progressively debilitating and fatal disease caused by mutations in the transthyretin (TTR) gene. …